LLL3

LLL3 (CLT-005) is a STAT3 inhibitor. LLL3 inhibits dimerization and phosphorylation of STAT3, thereby preventing intraconuclear transfer of STAT3 and inhibits the expression of STAT3 dependent genes, which encode proteins such as Bcl-xL and cyclin D1. In addition, LLL3 can induce cell growth inhibition and apoptosis in human breast cancer and rhabdomyosarcoma cells via the caspase pathway. LLL3 can be used in the study of STAT3 persistent activation types of cancer[1][2].

Product Specifications

CAS Number

[63972-38-3]

Product Name Alternative

CLT-005

UNSPSC

12352005

Target

Apoptosis; STAT

Type

Reference compound

Related Pathways

Apoptosis; JAK/STAT Signaling; Stem Cell/Wnt

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/lll3.html

Concentration

10mM

Purity

97.20

Solubility

DMSO : 20 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C1C2=C(C(O)=CC=C2)C(C3=CC=CC(C(C)=O)=C13)=O

Molecular Formula

C16H10O4

Molecular Weight

266.25

References & Citations

[1]Fuh B, et al. LLL-3 inhibits STAT3 activity, suppresses glioblastoma cell growth and prolongs survival in a mouse glioblastoma model[J]. British journal of cancer, 2009, 100 (1) : 106-112.|[2]Lavecchia A, et al. Novel inhibitors of signal transducer and activator of transcription 3 signaling pathway: an update on the recent patent literature[J]. Expert opinion on therapeutic patents, 2014, 24 (4) : 383-400.